Sildenafil Added Effect in Dapoxetine Non-responding Mono-symptomatic Premature Ejaculation (PE)

Overview

Study Design: Single Blind Placebo Controlled Randomized Trial, aiming to assess the efficacy and safety of adding sildinafile 50 mg to dapoxitine 30 mg in dapoxitine non responding premature ejaculation.

Study Design: Single Blind, Placebo Controlled Randomized Trial. Study Setting: Urology outpatient clinics at Al-Hussein and Sayed Galal Hospitals; Al-Azhar University; Cairo; Egypt. Timeline: 12 months \[8 months for data collection; 2 months for thesis writing and 2 months for publication\]. Study Population: * The study participants will be males suffering from primary or acquired mono-symptomatic premature ejaculation (PE) that did not respond to 2 months of dapoxetine monotherapy. * participants will considered to have PE if they fulfilled the criteria of the International Society for Sexual Medicine that defines PE as a male sexual dysfunction characterized by (i) ejaculation which always or nearly always occurs prior to or within 1 min of vaginal penetration, either present from the first sexual experience or following a new bothersome change in ejaculatory latency. (ii) Negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy(Gillman \& Gillman, 2019). * Other patient inclusion criteria will be: age ≥20 years old, married and in a stable regular sexual relationship for at least 3 months before the study. Exclusion criteria: * Men with associated erectile dysfunction (ED). * Men with associated chronic prostatitis. * Diabetes Mellitus (DM). * Advanced renal or hepatic diseases. * Neurological diseases and C.N.S. medications. * Contraindication to sildenafil as Nitric Oxide dependent ischemic heart disease patients or drug allergy. Study Sample: \- All available cases with complete medical record and accepted follow-up with us will be included. Study Procedures and Data Collection: * Single blind placebo randomized controlled trial will be conducted on 200 male participants with PE divided into two groups 100 participant in each. * The participants will be selected from those seeking medical advice at the outpatient clinics of Al-Hussein and Sayed Galal Hospitals; Al-Azhar University; Cairo; Egypt starting from October 2022. * An informed consent will be obtained by each participant after full explanation for the nature of the research. * The medical records of all adult males suffering from mono-symptomatic premature ejaculation who were treated with on demand dapoxetine for 2 months with no improvement and agree to participate in the study will be reviewed for, 1. Demographic and clinical data as, age, comorbidities, occupation, parity, body mass index. 2. Detailed medical and sexual history. 3. All patients will be evaluated by the International Index of Erectile Function 5 (IIEF5) item questionnaires to exclude those with erectile dysfunction (score ≥22) and premature ejaculation diagnostic tool (PEDT). 4. Physical examination including local abdominal and genital examination. 5. Urine analysis with culture and sensitivity. 6. Abdominopelvic ultrasonography. 7. If needed Penile duplex US and Or Nocturnal Penile Tumescence and Rigidity (NPTR)will be performed to exclude organic ED. Participants of our study will be enrolled into two groups (A and B). participants enrollment will be done by simple randomization method through which none of participants know in which group he will be. Group (A) will receive sildenafil 50mg as additive therapy to dapoxetine 30 mg for 8 weeks. Group (B) will continue on dapoxetine 30mg with placebo for the same period as group (A). All patients will be instructed to do sexual intercourse 2-3 times a week. * All patients were evaluated before and after the treatment by Premature Ejaculation Diagnostic Tool (PEDT) and IIEF-5, using the validated Arabic version of both questionnaires, Questionnaire will be fulfilled by face to face interview method. Protection of Participants: 1. The research will be explained in detail to the participants before inclusion in the study. 2. Participants will sign an informed written consent before enrollment. 3. Extreme care will be taken during the research related procedures. 4. It will be made clear that the subject has the full right to withdraw from the study at any time. 5. Informed consent and all study material will be kept in separate lockers; not accessed except by study investigators.

Conditions

Interventions

Eligibility

Outcomes

Central Contacts